Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: http://dx.doi.org/10.25673/92704
Titel: Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID)
Autor(en): Vasapolli, RiccardoIn der Gemeinsamen Normdatei der DNB nachschlagen
Schulz, ChristianIn der Gemeinsamen Normdatei der DNB nachschlagen
Schweden, Melanie
Casèn, Christina
Kirubakaran, Graceline Tina
Kirste, Katrine Hånes
Macke, LukasIn der Gemeinsamen Normdatei der DNB nachschlagen
Link, AlexanderIn der Gemeinsamen Normdatei der DNB nachschlagen
Schütte, KerstinIn der Gemeinsamen Normdatei der DNB nachschlagen
Malfertheiner, PeterIn der Gemeinsamen Normdatei der DNB nachschlagen
Erscheinungsdatum: 2021
Art: Artikel
Sprache: Englisch
URN: urn:nbn:de:gbv:ma9:1-1981185920-946602
Schlagwörter: Cytolethal distending toxin/ vinculin
Dysbiosis
Faecal microbiota
Functional dyspepsia
Irritable bowel syndrome
Zusammenfassung: Background: Distinct faecal microbiota profiles are reported to be associated with various subtypes of IBS. Circulating antibodies to cytolethal distending toxin B (CdtB) and vinculin are proposed as biomarkers to identify post-infectious IBS. The aim of our study was to analyse serum levels of anti-CdtB and anti-vinculin antibodies in patients with different functional gastrointestinal disorders (FGID) and their correlation with the composition of faecal microbiome. Methods: The study cohort comprised 65 prospectively recruited individuals: 15 with diarrhoea-type- IBS (IBS-D), 13 with constipation-type- IBS (IBS-C), 15 with functional dyspepsia (FD) and 22 healthy controls. FGID subgroups were defined according to Rome III criteria. Serum levels of anti-CdtB and anti-vinculin antibodies were measured by ELISA. Faecal microbiome composition analysis and assessment of dysbiosis were performed by GA-map ® Dysbiosis Test. Results: Positivity rate either for anti-CdtB or anti-vinculin antibodies was higher in the IBS-C group (76.9%) compared to IBS-D (40.0%), FD (60%) and healthy (63.6%) groups. Dysbiosis was more frequent in subjects positive for anti-CdtB antibodies and in IBS-C patients, who showed an increased amount of opportunistic/pro-inflammatory bacteria and reduced gut protective bacteria. IBS-C patients showed a high inter-individual variation of bacterial communities compared to other FGID subgroups and healthy individuals, whereas microbial profiles of patients with IBS-D and FD were overlapping with those of healthy controls. No bacteria markers showed significant differences between FGID subgroups and healthy controls. Conclusion: Neither anti-CdtB/ anti-vinculin antibodies nor faecal microbial profiles allowed to discriminate between specific FGID subgroups. Dysbiosis was more frequent in patients presenting with anti-CdtB antibodies and in IBS-C patients.
URI: https://opendata.uni-halle.de//handle/1981185920/94660
http://dx.doi.org/10.25673/92704
Open-Access: Open-Access-Publikation
Nutzungslizenz: (CC BY-NC-ND 4.0) Creative Commons Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International(CC BY-NC-ND 4.0) Creative Commons Namensnennung - Nicht kommerziell - Keine Bearbeitungen 4.0 International
Sponsor/Geldgeber: Projekt DEAL 2021
Journal Titel: European journal of clinical investigation
Verlag: Wiley-Blackwell
Verlagsort: Oxford [u.a.]
Band: 51
Heft: 12
Originalveröffentlichung: 10.1111/eci.13666
Seitenanfang: 1
Seitenende: 10
Enthalten in den Sammlungen:Medizinische Fakultät (OA)

Dateien zu dieser Ressource:
Datei Beschreibung GrößeFormat 
Vasapolli et al._Gut microbiota_2021.pdfZweitveröffentlichung410.38 kBAdobe PDFMiniaturbild
Öffnen/Anzeigen